New England Asset Management Inc. Sells 375 Shares of Amgen Inc. (NASDAQ:AMGN)

New England Asset Management Inc. lessened its position in Amgen Inc. (NASDAQ:AMGN) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,260 shares of the medical research company’s stock after selling 375 shares during the quarter. New England Asset Management Inc.’s holdings in Amgen were worth $5,884,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Meyer Handelman Co. lifted its position in shares of Amgen by 7.2% in the second quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock worth $40,566,000 after purchasing an additional 8,700 shares in the last quarter. Swiss National Bank increased its stake in Amgen by 0.3% in the 3rd quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company’s stock valued at $513,033,000 after buying an additional 5,500 shares during the last quarter. EP Wealth Advisors LLC lifted its position in Amgen by 11.0% during the 1st quarter. EP Wealth Advisors LLC now owns 23,769 shares of the medical research company’s stock worth $6,758,000 after buying an additional 2,353 shares in the last quarter. Mizuho Securities USA LLC boosted its stake in shares of Amgen by 88.8% during the 3rd quarter. Mizuho Securities USA LLC now owns 78,092 shares of the medical research company’s stock worth $25,162,000 after buying an additional 36,733 shares during the last quarter. Finally, Cornerstone Capital Inc. grew its holdings in shares of Amgen by 3.2% in the 3rd quarter. Cornerstone Capital Inc. now owns 106,538 shares of the medical research company’s stock valued at $34,328,000 after acquiring an additional 3,260 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Barclays upped their target price on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Wolfe Research began coverage on shares of Amgen in a research note on Friday. They issued a “peer perform” rating for the company. Finally, Oppenheimer restated an “outperform” rating and set a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Trading Down 0.9 %

AMGN stock opened at $278.76 on Tuesday. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The company has a market capitalization of $149.84 billion, a PE ratio of 35.69, a price-to-earnings-growth ratio of 2.53 and a beta of 0.60. The company’s 50-day simple moving average is $319.90 and its 200 day simple moving average is $318.65. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the prior year, the business posted $4.96 EPS. The business’s revenue was up 23.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a yield of 3.23%. Amgen’s dividend payout ratio is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.